Table 2.
Antiretroviral drugs currently approved by US Food and Drug Administration
| Entry | Reverse transcriptase |
Protease | |||
|---|---|---|---|---|---|
| Nucleoside | Nucleotide | Non-nucleoside | |||
| Single compound tablets | Enfuvirtide | Abacavir | Tenofovir | Delaviridine | (Fos)-Amprenavir |
| Didanosine | Efavirenz | Atazanavir | |||
| Emtricitabine | Nevirapine | Darunavir | |||
| Lamivudine | Indinavir | ||||
| Stavudine | Nelfinavir | ||||
| Zalcitabine | Ritonavir | ||||
| Zidovudine | Saquinavir | ||||
| Tripanavir | |||||
| Fixed-dose combination tablets | Abacavir/lamivudine (Epzicom) | Lopinavir/ritonavir | |||
| Zidovudine/lamivudine (Combivir) | |||||
| Tenofovir/emtricitabine (Truvada) | |||||
| Abacavir/lamivudine/zidovudine (Trizavir) | |||||
| Tenofovir/emtricitabine/efavirenz (Atripla) | |||||
Drugs belong to five drug classes and target three dir erent viral steps (entry, reverse transcription, or protease). Availability of these drugs in resource-limited countries is subject to country specific licensing agreements.